MarketCap
Facebook
X
Telegram
TCR2 Therapeutics ROE Ratio | TCRR
Annual ROE Ratio TCR2 Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -107.78 | -35.46 | -28.38 | -7.99 | 8.97 | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.97 | -107.78 | -34.13 |
Quarterly ROE Ratio TCR2 Therapeutics
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -80.65 | -40.78 | -49.35 | -41.33 | -33.52 | -22.11 | -29.91 | -28.05 | -32.83 | -37.26 | -37.45 | -38.81 | -32.7 | -27.27 | -10.31 | 5.21 | 18.49 | 28.3 | 7.45 | 7.22 | 4.65 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.3 | -80.65 | -22.43 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
21.18 | $ 547.4 | 0.9 % | $ 140 B |  USA |
 |
vTv Therapeutics
VTVT
|
-41.86 | $ 20.85 | -4.09 % | $ 82.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Eli Lilly and Company
LLY
|
77.78 | $ 1 363.22 | -0.33 % | $ 1.22 T | USA |
 |
Compugen Ltd.
CGEN
|
34.4 | $ 1.97 | 2.6 % | $ 184 M |  Israel |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-188.93 | $ 3.94 | 2.79 % | $ 48.1 M | Israel |
 |
Edesa Biotech
EDSA
|
-57.71 | $ 2.19 | 2.67 % | $ 12.4 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
38.19 | $ 62.15 | -1.6 % | $ 126 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
114.5 | $ 14.49 | 4.4 % | $ 937 M | USA |
 |
Moderna
MRNA
|
-32.62 | $ 253.93 | 5.17 % | $ 98.8 B | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-18.9 | $ 1.55 | -9.36 % | $ 1.04 B | Israel |
 |
Achieve Life Sciences
ACHV
|
-253.96 | $ 6.75 | 5.8 % | $ 294 M | USA |
 |
Amgen
AMGN
|
89.06 | $ 460.27 | 0.28 % | $ 248 B | USA |
 |
Armata Pharmaceuticals
ARMP
|
79.51 | $ 3.37 | 12.33 % | $ 122 M | USA |
 |
Axsome Therapeutics
AXSM
|
-207.46 | $ 132.34 | 1.95 % | $ 6.58 B | USA |
 |
Champions Oncology
CSBR
|
-29.83 | $ 4.8 | 0.85 % | $ 66.4 M | USA |
|
Forte Biosciences
FBRX
|
-113.75 | $ 76.99 | 0.03 % | $ 997 M | USA |
 |
Immunic
IMUX
|
1456.2 | $ 7.79 | 6.42 % | $ 1.21 B | USA |
 |
AC Immune SA
ACIU
|
-156.95 | $ 2.23 | 5.69 % | $ 225 M |  Schweiz |
 |
Aldeyra Therapeutics
ALDX
|
-76.49 | $ 0.64 | 4.12 % | $ 38.4 M | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M |  Canada |
 |
Precision BioSciences
DTIL
|
-49.57 | $ 10.62 | 7.6 % | $ 136 M | USA |
 |
AIM ImmunoTech
AIM
|
142.68 | $ 0.16 | 4.41 % | $ 259 K | USA |
 |
Ascendis Pharma A/S
ASND
|
140.05 | $ 256.91 | 1.37 % | $ 15.6 B |  Danmark |
 |
ANI Pharmaceuticals
ANIP
|
14.43 | $ 67.32 | -3.3 % | $ 1.35 B | USA |
 |
Actinium Pharmaceuticals
ATNM
|
-432.56 | $ 1.42 | 9.23 % | $ 44.3 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.29 | 2.38 % | $ 343 M |  Britain |
 |
BridgeBio Pharma
BBIO
|
35.13 | $ 74.28 | 0.01 % | $ 14.2 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
-221.45 | $ 7.69 | 0.72 % | $ 1.61 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
-35.9 | $ 3.6 | 3.45 % | $ 249 M | Britain |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 0.77 | 2.9 % | $ 90.2 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 25.59 | -5.24 % | $ 3.26 B | USA |
 |
Cellectis S.A.
CLLS
|
-89.05 | $ 1.09 | 5.83 % | $ 109 M |  France |
 |
BeyondSpring
BYSI
|
3.13 | $ 0.61 | -3.32 % | $ 25.1 M | USA |
 |
Alkermes plc
ALKS
|
13.29 | $ 45.88 | 3.01 % | $ 7.56 B |  Irlanda |
 |
Altimmune
ALT
|
-39.17 | $ 2.09 | 6.09 % | $ 184 M | USA |
 |
Cardiff Oncology
CRDF
|
-0.1 | $ 0.8 | 5.3 % | $ 53.5 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-58.83 | $ 0.55 | -1.2 % | $ 6.09 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-30.74 | $ 10.35 | 10.52 % | $ 283 M | Israel |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.35 | $ 58.16 | 1.22 % | $ 7.78 B | USA |
 |
Incyte Corporation
INCY
|
24.9 | $ 119.79 | 1.51 % | $ 23.4 B | USA |
 |
Atara Biotherapeutics
ATRA
|
-84.9 | $ 7.81 | -1.88 % | $ 98 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
49.4 | $ 16.32 | 0.68 % | $ 2.19 B | Canada |
 |
Cullinan Management
CGEM
|
-53.8 | $ 11.37 | 5.28 % | $ 685 M | USA |
 |
BioNTech SE
BNTX
|
-5.91 | $ 87.46 | 1.86 % | $ 21.1 B |  Germany |
 |
Collegium Pharmaceutical
COLL
|
20.88 | $ 24.19 | -3.86 % | $ 766 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-53.24 | $ 3.07 | 7.34 % | $ 40.9 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
63.85 | $ 1.26 | -0.79 % | $ 57.6 M | Israel |
 |
AnaptysBio
ANAB
|
1237.56 | $ 46.46 | 1.92 % | $ 1.35 B | USA |
 |
Assembly Biosciences
ASMB
|
-2.96 | $ 20.43 | 2.17 % | $ 229 M | USA |